AMNEAL PHARMACEUTICALS, INC. (AMRX) Free cash flow 2016–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$269.9MFY2025 · since FY2016: -$7.7M → $269.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $269.9M | +11.0% |
| FY2024 | $243.2M | -19.6% |
| FY2023 | $302.4M | +1517.5% |
| FY2022 | $18.7M | -90.4% |
| FY2021 | $194.1M | -39.8% |
| FY2020 | $322.6M | +809.3% |
| FY2019 | -$45.5M | -127.2% |
| FY2018 | $167.1M | +19.9% |
| FY2017 | $139.4M | +1911.5% |
| FY2016 | -$7.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Gross marginAMRX Operating incomeAMRX Operating marginAMRX Operating cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →